NCT06298019
Study of KYV-101 Anti-CD19 CAR T Therapy in Adult Dermatomyositis
At risk: Primary completion moved at least 32 days later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
Notable Eligibility criteria expanded, about 52 words Show 4 more changesShow less
- Enrollment closed, study ongoing
- Primary completion pushed from Apr 2027 to Jun 2027
- Study completion moved earlier from Apr 2039 to Jul 15, 2027
- Site details revised at 2 of 2 sites
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date changed from estimate of Apr 2024 to Aug 2, 2024
- Study sites: 1 to 2
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Number of participants experiencing adverse events
Timeframe: 24 weeks
Arms and interventions
Active Intervention with CAR TExperimental
All participants in the trial will receive an infusion of autologous, genetically modified CAR T cells specific for the CD19 antigen
Biologicals: KYV-101
Sites
2 sites in 1 country